In cancer, PPAR agonist administration induces fatty acid oxidation (FAO) in CD8+ T cells, enhancing anti-tumor immunity, and facilitates anti-programmed cell death protein 1 (PD-1) immunotherapy (Chowdhury et al., 2018). The gene discussed is PDCD1; the disease is neoplasm.